ArticleRisk management and healthcare policy2026
A Real-World Study on Medical Resource Consumption in Multidrug-Resistant Organism Infections Under the DRG Payment Model.
Article in Risk management and healthcare policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Diagnosis-Related Groups (DRG) has become the predominant approach in China, while infections with multidrug-resistant organisms (MDRO) increase patient length of stay (LOS) and costs. Quantifying the impact of MDRO infections on medical resource consumption, providing a basis for hospitals' precise prevention and cost management. Patients and Methods: A retrospective analysis was conducted on discharge patient data from a Grade A tertiary general hospital in China, from January 2023 to December 2024. Resource consumption was compared between MDRO-infected (by different sources and types) and non-infected groups. There were 953 patients in the MDRO-infected group and 210,608 in the non-MDRO-infected group. Differences in median LOS and hospitalization costs were further analyzed through DRGs stratification. Results: The overall incidence of MDRO infections was 0.571‰. The MDRO-infected (by different sources and types) had higher Time Consumption Index (TCI) and Cost Consumption Index (CCI) than the non-infected group ( Conclusion: MDRO infections substantially increase medical resource consumption. Strengthening the control of high-incidence MDRO DRG is necessary to help hospitals adapt to the DRG payment model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.